Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

News provided by

May 10, 2012, 06:34 ET

NEW YORK, May 10, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

http://www.reportlinker.com/p0849622/Commercializing-Pancreatic-Cancer-Drugs-The-Faster-Route-to-Consider-Your-Options-and-Position-of-Others.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

This report will excel your competitive awareness and decrease your decision making time in managing pancreatic cancer drug development. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

This report comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in pancreatic cancer. BioSeeker has applied its unique drug assessment methodology to stratify the pancreatic cancer drug pipeline and discern the level of competition in fine detail.

Major Findings from this report:

* The identified competitive landscape of pancreatic cancer drugs is split between the half which have unique drug target strategies and the other half which have head-to-head target competing drugs in 37 different clusters. The latter has a competing ratio which is more than two times higher than the comparable average of the pancreatic cancer drugs in general.

* Nine out of every ten drug target strategies in Phase III and Phase II development are new to pancreatic cancer drugs.

* The greatest number of new target strategies are found in Phase II (37%) and Phase I (18%) development.

* Small molecules, Antibodies and Reformulated drugs are the dominating compound strategies of pancreatic cancer drugs, which represent almost 80% of the entire pipeline.

* Besides Reformulated drugs, it is Protein and Peptide based pancreatic cancer drugs that have the highest cross-over of drug target strategies with other compound strategies, especially with that of Antibodies.

* The highest number of described drug target strategies of pancreatic cancer drugs belongs to Pfizer, Hoffmann-La Roche, Novartis and AstraZeneca.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any pancreatic cancer drug in cancer to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 32 About Cancer Highlights™ 52.1 Cancer Focus Areas 52.2 Subscribe Today and Start Saving 62.2.1 Type of License 62.3 Additional Information 62.4 BioSeeker Group's Oncology Team 63 Methodology 73.1 Cancer Highlights'™ Five Pillar Drug Assessment 74 Table of Contents 94.1 List of Figures 194.2 List of Tables 195 Introduction 275.1 The Scope of this Report 275.2 Definitions 305.3 Abbreviations 306 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment 316.1 Drug Repositioning in Oncology 316.2 Introduction to Targets of Pancreatic Cancer Drugs 326.2.1 Carboxy-lyase Activity Targets 396.2.2 Catalytic Activity Targets 406.2.3 Cell Adhesion Molecule Activity Targets 516.2.4 Chaperone Activity Targets 596.2.5 Cofactor Binding Targets 606.2.6 Cysteine-type Peptidase Activity Targets 626.2.7 Cytokine Activity Targets 696.2.8 DNA Binding Targets 756.2.9 DNA Repair Protein Targets 776.2.10 DNA Topoisomerase Activity Targets 806.2.11 DNA-directed DNA Polymerase Activity Targets 856.2.12 Extracellular Ligand-gated Ion Channel Activity Targets 926.2.13 Extracellular Matrix Structural Constituent Targets 946.2.14 G-protein Coupled Receptor Activity Targets 986.2.15 Growth Factor Activity Targets 1086.2.16 GTPase Activity Targets 1146.2.17 Hormone Activity Targets 1236.2.18 Hydrolase Activity Targets 1246.2.19 Ion Channel Activity Targets 1256.2.20 Kinase Activity Targets 1266.2.21 Kinase Binding Targets 1386.2.22 Kinase Regulator Activity Targets 1396.2.23 Ligand-dependent Nuclear Receptor Activity Targets 1436.2.24 Ligase Activity Targets 1446.2.25 Lipase activity 1506.2.26 Lipid kinase activity 1516.2.27 Lipid Phosphatase Activity Targets 1546.2.28 Molecular Function Unknown Targets 1556.2.29 Motor Activity Targets 1656.2.30 Oxidoreductase Activity Targets 1676.2.31 Peptidase Activity Targets 1736.2.32 Peptide Hormone Targets 1836.2.33 Peroxidase Activity Targets 1856.2.34 Protein Binding Targets 1866.2.35 Protein Serine/Threonine Kinase Activity Targets 1886.2.36 Protein Threonine/Tyrosine Kinase Activity Targets 2136.2.37 Protein Tyrosine Phosphatase Activity Targets 2186.2.38 Protein-tyrosine Kinase Activity Targets 2266.2.39 Receptor Activity Targets 2376.2.40 Receptor Binding Targets 2556.2.41 Receptor Signaling Complex Scaffold Activity Targets 2606.2.42 RNA Binding Targets 2646.2.43 RNA-directed DNA Polymerase Activity Targets 2656.2.44 Serine-type Peptidase Activity Targets 2666.2.45 Structural Constituent of Cytoskeleton Targets 2716.2.46 Structural Molecule Activity Targets 2736.2.47 Transcription Factor Activity Targets 2746.2.48 Transcription Regulator Activity Targets 2926.2.49 Transferase Activity Targets 2986.2.50 Translation Regulator Activity Targets 2996.2.51 Transmembrane Receptor Activity Targets 3016.2.52 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 3046.2.53 Transporter Activity Targets 3406.2.54 Unclassified Targets 3456.2.55 Voltage-gated Ion Channel Activity Targets 3466.2.56 Other Targets 3476.3 The Cancer Genome Project and Targets of Pancreatic Cancer Drugs 3486.3.1 Targets of Pancreatic Cancer Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 3486.4 Pancreatic Cancer Therapeutics is Stimulated by Available Structure Data on Targets 3546.5 Target-Target Interactions among Identified Targets of Pancreatic Cancer Drugs 3586.6 The Drug-Target Competitive Landscape 3626.7 Protein Expression Levels of Identified Targets of Pancreatic Cancer Drugs 3666.8 Pathway Assessment of Pancreatic Cancer Drugs 3696.8.1 Tools for Analysis of Cancer Pathways 3706.8.2 Pathway Assessment 3717 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development 4237.1 Registered to Marketed: New and Unique Drug Target Strategies of Pancreatic Cancer Drugs 4257.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Pancreatic Cancer Drugs 4267.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Pancreatic Cancer Drugs 4287.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Pancreatic Cancer Drugs 4337.5 Preclinical Development: New and Unique Drug Target Strategies of Pancreatic Cancer Drugs 4367.6 Drug Target Strategies of Suspended or Terminated Pancreatic Cancer Drugs 4387.7 Target Strategy Development Profiles of Pancreatic Cancer Drugs 4407.7.1 Marketed 4447.7.2 Phase III 4477.7.3 Phase II 4627.7.4 Phase I 5227.7.5 Preclinical 5527.7.6 Suspended 5757.7.7 Ceased 5777.8 The Competition Through Close Mechanistic Approximation of Pancreatic Cancer Drugs 6098 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy 6138.1 Small Molecules 6158.1.1 Background 6158.1.2 Target Strategies of Small Molecule Drugs 6168.2 Peptide & Protein Drugs 6248.2.1 Background 6248.2.2 Target Strategies of Peptide and Protein Drugs 6258.3 Antibodies 6308.3.1 Background 6308.3.2 Target Strategies of Antibody Drugs 6308.4 Nucleic Acid Therapies 6348.4.1 Background 6348.4.2 Target Strategies of Nucleic Acid Drugs 6358.5 Cell & Gene Therapy 6378.5.1 Background 6378.5.2 Target Strategies of Cell and Gene Therapy Drugs 6388.6 Drug Delivery and Nanotechnology 6428.6.1 Background 6428.6.2 Target Strategies of Reformulated Drugs 6428.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 6459 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator 6529.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 6569.2 Company Facts and Ranking 6589.3 Competitive Fall-Out Assessment 6669.4 AB Science 6689.5 Abbott 6709.6 Active Biotech 6739.7 Advantagene 6759.8 Advaxis 6789.9 AEgera 6819.10 Aida Pharmaceuticals 6839.11 Amgen 6859.12 Antisense Pharma 6909.13 Anza Therapeutics 6929.14 Apogee Biotechnology 6949.15 Apotex 6969.16 Ardea Biosciences 6989.17 Ariad 7019.18 ArQule 7039.19 Array BioPharma 7059.20 Astellas 7099.21 AstraZeneca 7149.22 AVEO 7199.23 AVI BioPharma 7219.24 Bayer 7249.25 Betapharma 7279.26 Biogen Idec 7309.27 Bionovo 7339.28 BioNumerik 7359.29 BioSante 7389.30 Boehringer Ingelheim 7409.31 Bristol-Myers Squibb 7429.32 BTG 7479.33 Calando Pharmaceuticals 7519.34 Cancer Advances 7539.35 Cancer Research Technology 7559.36 Celera 7579.37 Celgene 7599.38 Cell Therapeutics 7639.39 Celldex Therapeutics 7669.40 Celsion 7699.41 Celtic Pharma 7729.42 Center of Molecular Immunology 7749.43 CG Therapeutics 7779.44 CompleGen 7809.45 Cornerstone Pharmaceuticals 7829.46 CritiTech 7849.47 Curaxis 7879.48 Curis 7899.49 Cyclacel 7919.50 Cylene Pharmaceuticals 7939.51 Cynvec 7959.52 CytImmune Sciences 7979.53 Cytokinetics 7999.54 CytRx 8019.55 Daiichi Sankyo 8049.56 Dara Biosciences 8099.57 EGEN Inc 8119.58 Eisai 8139.59 Eli Lilly 8189.60 EntreMed 8239.61 Epeius Biotechnologies 8259.62 EpiCept 8279.63 Esperance Pharmaceuticals 8309.64 Exelixis 8329.65 FibroGen 8349.66 Galectin Therapeutics 8369.67 Genta 8399.68 GenVec 8419.69 Geron 8439.70 GlaxoSmithKline 8459.71 GlycoGenesys 8509.72 Hoffmann-La Roche 8529.73 Human Genome Sciences 8589.74 ImmunoCellular Therapeutics 8609.75 ImmunoGen 8629.76 Immunomedics 8659.77 ImmuPharma 8699.78 Immutep 8719.79 Innate Pharma 8739.80 Innovive 8759.81 Insmed 8789.82 Insys Therapeutics 8819.83 Introgen Therapeutics 8879.84 Ipsen 8899.85 Johnson & Johnson 8929.86 Kadmon 8949.87 Kyowa Hakko Kirin 8969.88 Leo 8989.89 MBiotec 9009.90 Meda 9029.91 MediGene 9049.92 Medisyn Technologies 9089.93 Merck & Co 9109.94 Merck KGaA 9149.95 Merrimack 9189.96 Mersana Therapeutics 9219.97 MethylGene 9249.98 Micromet 9269.99 Nektar Therapeutics 9289.100 Nereus Pharmaceuticals 9319.101 Nippon Kayaku 9339.102 Nippon Shinyaku 9369.103 Non-industrial Source 9389.104 Novacea 9419.105 NovaLead 9449.106 Novartis 9479.107 Novogen 9539.108 OncoMed 9559.109 OncoTherapy Science 9579.110 Oncothyreon 9599.111 Oncozyme Pharma 9619.112 Oxford BioMedica 9639.113 OXiGENE 9659.114 Paladin Labs 9679.115 PanaGin 9709.116 Patrys 9729.117 Pepscan Therapeutics 9749.118 Pfizer 9769.119 Pharmacyclics 9839.120 PharmaMar 9859.121 Pharmexa 9879.122 Pierre Fabre 9909.123 Piramal 9939.124 ProMetic Life Sciences 9959.125 Protgen 9979.126 Ras Therapeutics 9999.127 Reata Pharmaceuticals 10019.128 Regeneron 10039.129 Regulon 10059.130 RESprotect 10079.131 Rexahn 10099.132 Rigel 10129.133 Rottapharm Madaus 10149.134 Samyang 10179.135 Sanofi 10219.136 Santaris Pharma 10269.137 Shire 10289.138 SuperGen 10309.139 Taiho 10349.140 Takeda 10389.141 Talon Therapeutics 10409.142 Tapestry Pharmaceuticals 10439.143 Tau Therapeutics 10469.144 Teva 10489.145 Thallion Pharmaceuticals 10509.146 Therion Biologics 10529.147 Titan Pharmaceuticals 10549.148 TopoTarget 10579.149 Tragara Pharmaceuticals 10609.150 Trion Pharma 10629.151 UMN Pharma 10649.152 VaxOnco 10669.153 Vertex Pharmaceuticals 10689.154 Vion Pharmaceuticals 10709.155 VioQuest 10729.156 ViroMed 10759.157 Wilex 10789.158 Xerion 10809.159 Yakult Honsha 10829.160 YM BioSciences 10859.161 Zeria 1088Disclaimer 109010 Drug Index 109111 Company Index 1098

4.1 List of Figures

Figure 1: Visualization of Target-Target Interactions among Targets of Pancreatic Cancer Drugs 361

Figure 2: The Drug-Target Competitive Landscape of Pancreatic Cancer Drugs - Large Clusters 363

Figure 3: The Drug-Target Competitive Landscape Pancreatic Cancer Drugs - Smaller Clusters 364

Figure 4: Head-to-Head Targeting Competitive Landscape of Pancreatic Cancer Drugs 365

Figure 5: Distribution of Compound Strategies among Pancreatic Cancer Drugs 645

Figure 6: Primary Sub-cellular Localization of Drug Targets 646

Figure 7: Number of Companies per Ranking Level 661

4.2 List of Tables

Table 1: Cancer Highlights'™ Five Pillar Drug Assessment 7Table 2: Breakdown of the Included Pancreatic Cancer Drug Pipeline by Stage of Development 27Table 3: Head to Head Target Competition among Pancreatic Cancer Drugs 27Table 4: Overview of Drug Target Strategy Themes 32Table 5: Terminally Ceased Targets of Pancreatic Cancer Drugs 33Table 6: Official Gene Symbol to Target Profle 34Table 7: Targets of Pancreatic Cancer Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 349Table 8: Identity of Drug Targets with Available Biological Structures 354Table 9: Number of Target-Target Interactions among Targets of Pancreatic Cancer Drugs 359Table 10: Available Protein Expression Profiles of Pancreatic Cancer Drug Targets 366Table 11: Pathway Summary 371Table 12: Drug Targets without any Identified Assigned Pathways 371Table 13: Pathway Profiles According to BioCarta of Pancreatic Cancer Drug Targets 373Table 14: Pathway Profiles According to KEGG of Pancreatic Cancer Drug Targets 392Table 15: Pathway Profiles According to NetPath of Pancreatic Cancer Drug Targets 415Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 423Table 17: Top Competitive Target Strategies of Pancreatic Cancer Drugs 424Table 18: New and Unique Target Strategies of Registered and Marketed Pancreatic Cancer Drugs 425Table 19: The Competition Through Close Mechanistic Approximation Between Pancreatic Cancer Drugs in Registered to Marketed 425Table 20: New and Unique Target Strategies in Phase III Clinical Development of Pancreatic Cancer Drugs 426Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Pancreatic Cancer Drugs 427Table 22: New and Unique Target Strategies in Phase II Clinical Development of Pancreatic Cancer Drugs 428Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Pancreatic Cancer Drugs 431Table 24: New and Unique Target Strategies in Phase I Clinical Development of Pancreatic Cancer Drugs 433Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Pancreatic Cancer Drugs 435Table 26: New and Unique Target Strategies in Preclinical Development of Pancreatic Cancer Drugs 436Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Pancreatic Cancer Drugs 437Table 28: Target Strategies of Suspended or Terminated Pancreatic Cancer Drugs 438Table 29: Connecting Target Strategy with Its Profile Identification Number 440Table 30: The Competition Through Close Mechanistic Approximation Among Pancreatic Cancer Drugs 609Table 31: Overview of Compound Strategy Competition Among Pancreatic Cancer Drugs 614Table 32: Overview of the Competitive Landscape of Small Molecule Based Pancreatic Cancer Drugs 616Table 33: Competitive Comparison of Target Strategies of Small Molecule Pancreatic Cancer Drugs 617Table 34: Pursued Target Strategies of Small Molecule Drugs Based Pancreatic Cancer Drugs 619Table 35: Overview of the Competitive Landscape of Peptide Based Pancreatic Cancer Drugs 625Table 36: Competitive Comparison of Target Strategies of Peptide Based Pancreatic Cancer Drugs 626Table 37: Pursued Target Strategies of Peptide Based Pancreatic Cancer Drugs 626Table 38: Overview of the Competitive Landscape of Protein Based Pancreatic Cancer Drugs 628Table 39: Pursued Target Strategies of Protein Based Pancreatic Cancer Drugs 629Table 40: Overview of the Competitive Landscape of Antibody Based Pancreatic Cancer Drugs 630Table 41: Competitive Comparison of Target Strategies of Antibody Based Pancreatic Cancer Drugs 631Table 42: Pursued Target Strategies of Antibody Based Pancreatic Cancer Drugs 632Table 43: Overview of the Competitive Landscape of Nucleic Acid Based Pancreatic Cancer Drugs 635Table 44: Competitive Comparison of Target Strategies of Nucleic Acid Based Pancreatic Cancer Drugs 636Table 45: Pursued Target Strategies of Nucleic Acid Based Pancreatic Cancer Drugs 636Table 46: Potential Forms of Cell Therapy 637Table 47: Vectors in Gene Therapy 638Table 48: Overview of the Competitive Landscape of Cell Therapy Based Pancreatic Cancer Drugs 638Table 49: Pursued Target Strategies of Cell Therapy Based Pancreatic Cancer Drugs 639Table 50: Overview of the Competitive Landscape of Gene Therapy Based Pancreatic Cancer Drugs 640Table 51: Competitive Comparison of Target Strategies of Gene Therapy Based Pancreatic Cancer Drugs 641Table 52: Pursued Target Strategies of Gene Therapy Based Pancreatic Cancer Drugs 641Table 53:Overview of the Competitive Landscape of Reformulated Pancreatic Cancer Drugs 642Table 54: Competitive Comparison of Target Strategies of Reformulated Pancreatic Cancer Drugs 643Table 55: Pursued Target Strategies of Reformulated Pancreatic Cancer Drugs 644Table 56: Compound Strategies based on Sub-Cellular Localization of Pancreatic Cancer Drug Targets 646Table 57: Competitive Summary by Investigator of Pancreatic Cancer Drug Development 652Table 58: Summary Table of Corporate Changes in the Competitive Landscape of Pancreatic Cancer Drug Development 656Table 59: The Worst Ranking and the Highest Populated Level for Each of the 15 Ranking Parameters 660Table 60: Example of a Competitive Fall-Out Table (Targeting TYMS/Modified) 666Table 61: AB Science's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 669Table 62: Abbott's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 672Table 63: Active Biotech's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 674Table 64: Advantagene's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 677Table 65: Advaxis' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 680Table 66: AEgera's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 682Table 67: Aida Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 684Table 68: Amgen's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 687Table 69: Antisense Pharma's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 691Table 70: Anza Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 693Table 71: Apogee Biotechnology's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 695Table 72: Apotex's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 697Table 73: Ardea Biosciences' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 700Table 74: Ariad's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 702Table 75: ArQule's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 704Table 76: Array BioPharma's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 707Table 77: Astellas' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 711Table 78: AstraZeneca's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 716Table 79: AVEO's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 720Table 80: AVI BioPharma's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 723Table 81: Bayer's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 725Table 82: Betapharma's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 729Table 83: Biogen Idec's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 732Table 84: Bionovo's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 734Table 85: BioNumerik's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 737Table 86: BioSante's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 739Table 87: Boehringer Ingelheim's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 741Table 88: Bristol-Myers Squibb's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 744Table 89: BTG's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 749Table 90: Calando Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 752Table 91: Cancer Advances' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 754Table 92: Cancer Research Technology's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 756Table 93: Celera's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 758Table 94: Celgene's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 761Table 95: Cell Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 765Table 96: Celldex Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 768Table 97: Celsion's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 771Table 98: Celtic Pharma's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 773Table 99: Center of Molecular Immunology's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 776Table 100: CG Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 779Table 101: CompleGen's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 781Table 102: Cornerstone Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 783Table 103: CritiTech's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 786Table 104: Curaxis' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 788Table 105: Curis' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 790Table 106: Cyclacel's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 792Table 107: Cylene Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 794Table 108: Cynvec's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 796Table 109: CytImmune Sciences' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 798Table 110: Cytokinetics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 800Table 111: CytRx's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 803Table 112: Daiichi Sankyo's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 807Table 113: Dara Biosciences' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 810Table 114: EGEN Inc's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 812Table 115: Eisai's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 815Table 116: Eli Lilly's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 820Table 117: EntreMed's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 824Table 118: Epeius Biotechnologies' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 826Table 119: EpiCept's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 829Table 120: Esperance Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 831Table 121: Exelixis' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 833Table 122: FibroGen's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 835Table 123: Galectin Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 838Table 124: Genta's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 840Table 125: GenVec's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 842Table 126: Geron's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 844Table 127: GlaxoSmithKline's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 847Table 128: GlycoGenesys' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 851Table 129: Hoffmann-La Roche's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 854Table 130: Human Genome Sciences' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 859Table 131: ImmunoCellular Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 861Table 132: ImmunoGen's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 864Table 133: Immunomedics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 867Table 134: ImmuPharma's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 870Table 135: Immutep's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 872Table 136: Innate Pharma's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 874Table 137: Innovive's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 877Table 138: Insmed's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 880Table 139: Insys Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 884Table 140: Introgen Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 888Table 141: Ipsen's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 891Table 142: Johnson & Johnson's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 893Table 143: Kadmon's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 895Table 144: Kyowa Hakko Kirin's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 897Table 145: Leo's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 899Table 146: MBiotec's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 901Table 147: Meda's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 903Table 148: MediGene's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 906Table 149: Medisyn Technologies' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 909Table 150: Merck & Co's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 912Table 151: Merck KGaA's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 916Table 152: Merrimack's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 920Table 153: Mersana Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 923Table 154: MethylGene's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 925Table 155: Micromet's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 927Table 156: Nektar Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 930Table 157: Nereus Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 932Table 158: Nippon Kayaku's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 935Table 159: Nippon Shinyaku's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 937Table 160: Non-industrial source's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 940Table 161: Novacea's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 943Table 162: NovaLead's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 946Table 163: Novartis' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 949Table 164: Novogen's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 954Table 165: OncoMed's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 956Table 166: OncoTherapy Science's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 958Table 167: Oncothyreon's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 960Table 168: Oncozyme Pharma's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 962Table 169: Oxford BioMedica's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 964Table 170: OXiGENE's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 966Table 171: Paladin Labs' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 969Table 172: PanaGin's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 971Table 173: Patrys' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 973Table 174: Pepscan Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 975Table 175: Pfizer's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 978Table 176: Pharmacyclics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 984Table 177: PharmaMar's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 986Table 178: Pharmexa's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 989Table 179: Pierre Fabre's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 992Table 180: Piramal's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 994Table 181: ProMetic Life Sciences' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 996Table 182: Protgen's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 998Table 183: Ras Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1000Table 184: Reata Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1002Table 185: Regeneron's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1004Table 186: Regulon's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1006Table 187: RESprotect's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1008Table 188: Rexahn's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1011Table 189: Rigel's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1013Table 190: Rottapharm Madaus' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1016Table 191: Samyang's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1019Table 192: Sanofi's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1023Table 193: Santaris Pharma's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1027Table 194: Shire's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1029Table 195: SuperGen's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1032Table 196: Taiho's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1036Table 197: Takeda's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1039Table 198: Talon Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1042Table 199: Tapestry Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1045Table 200: Tau Therapeutics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1047Table 201: Teva's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1049Table 202: Thallion Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1051Table 203: Therion Biologics' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1053Table 204: Titan Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1056Table 205: TopoTarget's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1059Table 206: Tragara Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1061Table 207: Trion Pharma's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1063Table 208: UMN Pharma's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1065Table 209: VaxOnco's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1067Table 210: Vertex Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1069Table 211: Vion Pharmaceuticals' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1071Table 212: VioQuest's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1074Table 213: ViroMed's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1077Table 214: Wilex's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1079Table 215: Xerion's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1081Table 216: Yakult Honsha's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1084Table 217: YM BioSciences' Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1087Table 218: Zeria's Included Pancreatic Cancer Drug Pipeline and Competitive Fall-Out 1089

To order this report:Drug and Medication Industry: Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Market Research Report

Check our

Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker